Related Experiment Video

Updated: Oct 9, 2025

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice
10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

28.1K

Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation

Pitchaphon Nissaisorakarn1, Martha Pavlakis1, Amtul Aala1

  • 1Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Transplant Institute, Boston, MA.

Advances in Chronic Kidney Disease
|December 19, 2021
PubMed

Insights

Post-transplant diabetes mellitus (PTDM) increases risks in solid organ transplantation (SOT). Newer diabetes drugs, SGLT2 inhibitors and GLP-1 RAs, show promise but require more research in SOT patients.

Area of Science:

  • Nephrology
  • Endocrinology
  • Transplantation

Background:

  • Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation (SOT), significantly increasing patient morbidity and mortality.
  • Existing diabetes management strategies may not fully address the unique challenges in SOT recipients.

Purpose of the Study:

  • To review the current literature on the use of novel glucose-lowering agents in SOT recipients.
  • To examine the mechanisms of action, benefits, risks, and safety profiles of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the SOT population.

Main Methods:

  • Literature review of studies investigating SGLT2is and GLP-1 RAs in SOT patients.
  • Analysis of available data on efficacy, safety, and specific considerations for these agents in the context of transplantation.

Main Results:

  • Limited data currently exists on the use of SGLT2is and GLP-1 RAs in SOT.
  • These novel agents offer potential cardiovascular and renal benefits, but their specific impact and safety in SOT require further investigation.

Conclusions:

  • SGLT2 inhibitors and GLP-1 receptor agonists represent a promising therapeutic avenue for managing PTDM in SOT.
  • Further research is crucial to establish optimal use, efficacy, and safety profiles of these agents in solid organ transplant recipients.
Keywords:
Diabetes mellitusGlucagon-like peptide 1Kidney diseasePost-transplant diabetes mellitusSodium-glucose co-transporter 2Solid organ transplantation

More Related Videos

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation17:42

A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation

Published on: April 13, 2011

64.6K
Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

3.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
336
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
308
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
467
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
293
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
282
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
436